US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Genelux Corporation
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
September 09, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
June 30, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 07, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 19, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in Upcoming Conferences
February 18, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
January 12, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
January 08, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Proposed Public Offering of Common Stock
January 07, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
January 05, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
January 02, 2026
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
November 05, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
September 02, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
August 07, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
July 07, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
May 06, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
May 01, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 28, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
March 25, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
March 25, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
March 25, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces New Chief Financial Officer
February 03, 2025
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
December 13, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
November 14, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
November 06, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
October 22, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
October 09, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
August 14, 2024
From
Genelux Corporation
Via
GlobeNewswire
Tickers
GNLX
